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SUMMARY
A case-control study was conducted to examine the association among the Montenegro skin test (MST), age of skin lesion and 
therapeutic response in patients with cutaneous leishmaniasis (CL) treated at Evandro Chagas National Institute of Infectious Diseases 
(INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil. For each treatment failure (case), two controls showing skin 
lesion healing following treatment, paired by sex and age, were randomly selected. All patients were treated with 5 mg Sb5+/kg/day 
of intramuscular meglumine antimoniate (Sb5+) for 30 successive days. Patients with CL were approximately five times more likely 
to fail when lesions were less than two months old at the first appointment. Patients with treatment failure showed less intense MST 
reactions than patients progressing to clinical cure. For each 10 mm of increase in MST response, there was a 26% reduction in the 
chance of treatment failure. An early treatment - defined as a treatment applied for skin lesions, which starts when they are less than 
two months old at the first appointment -, as well as a poor cellular immune response, reflected by lower reactivity in MST, were 
associated with treatment failure in cutaneous leishmaniasis.
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INTRODUCTION
American tegumentary leishmaniasis (ATL) is an anthropozoonosis 
widely spread throughout Brazil. There were 21,866 new cases in 
20105,8, with two main forms: cutaneous leishmaniasis (CL) and mucosal 
leishmaniasis. The localized form of CL, presenting as single or multiple 
ulcers, is the most typical one5.
Culture of biopsy specimens of suspected lesions and the direct 
smear of material obtained from the lesion are the main confirmatory 
tests. Diagnosis may also be established by detection of parasites in 
histological specimens and by the polymerase chain reaction13. Due to 
high cost and technical complexity of tests, culture parasite and molecular 
detection of Leishmania in Brazil are restricted to the reference centers 
for this disease5,13. The Montenegro skin test (MST), with a sensitivity 
rate of 86.4% up to 100%6,15,23,29, is the main diagnostic test in primary 
care. In the presence of a suspicious cutaneous lesion, MST supports the 
diagnosis of Leishmania infection. Skin reactions to MST ≥ 5 mm are 
considered positive and < 5 mm are considered negative5. Patients with 
negative MST and diagnostic confirmation by other tests are more prone 
to relapse22. MST is a marker of cellular immune response10, evaluating 
type IV hypersensitivity response mediated by T cells28. However, it 
may be influenced by clinical presentation18 and by disease duration7,15. 
The first choice for CL drug treatment in Brazil is meglumine 
antimoniate (Sb5+)5. The Brazilian Ministry of Health (2010) recommends 
10 - 20 mg Sb5+/kg/day for 20 days. However, clinical studies in Rio 
de Janeiro suggest that 5 mg Sb5+/kg/day for 30 days may be easier to 
deliver, allowing effective treatment of the disease, with lower toxicity 
and cost19-21. 
Therapeutic failure is defined by DEPS et al. (2000) as lack of clinical 
response during and after the treatment, with stabilization or worsening of 
the ulcerated lesion12. In individuals treated with meglumine antimoniate 
with 10-20 mg Sb5+/kg/day, therapeutic failure varies from 46% to 
75%12,25,31,32. Factors related to therapeutic failure include: three or more 
cutaneous lesions, prior treatment to leishmaniasis, weight exceeding 
68 kg and irregular treatment27. 
In this study, the association among MST, age of cutaneous lesion 
and therapeutic response in patients with CL was evaluated. 
MATERIALS AND METHODS
1. Study design: This was an observational retrospective case-
control study, with localized CL patients who attended the Leishmaniasis 
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Surveillance Laboratory (Lab Vigileish) at Evandro Chagas National 
Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation 
(FIOCRUZ), Rio de Janeiro, Brazil, between January 1989 and 
December 2009. 
2. Inclusion criteria: Patients with CL diagnosis made by 
parasitological criteria (culture of Leishmania in appropriate media, 
parasites seen at histological exam or direct smear and/or imprint of a 
biopsy specimen; or Leishmania DNA detection by polymerase chain 
reaction) and/or epidemiological (patients living or travelling to endemic 
areas) and/or clinical (suggestive cutaneous lesions) and/or immunological 
criteria (Leishmania serology – indirect immunofluorescence reaction 
and/or immunoenzymatic assay) were included. They were treated 
with intramuscular meglumine antimoniate 5 mg Sb5+/kg/day for 30 
consecutive days29. 
3. Exclusion criteria: Patients with other clinical forms of CL, 
without register of MST in millimeters, lack of post-treatment follow-
up for at least two years, and/or those presenting relapse after an initial 
response (temporary healing) were excluded. 
4. Selection of cases and controls: Therapeutic failures, defined as 
the non-occurrence of progression to definitive scar formation after the 
initial treatment, were considered as cases.
Patients with permanent clinical cure, defined as the epithelization of 
the ulcerated lesions with progressive disappearance of crusts, scaling, 
infiltration and erythema, with a final establishment of an atrophic, 
hypertrophic or imperceptible scar, as well as the lack of mucosal lesion 
after the initial treatment, were considered as controls. Controls were 
randomly selected among the patients with clinical cure and were matched 
by sex and age range to the cases in the proportion of 2:1. Matching was 
performed according to the following age ranges: 5-9; 10-14; 15-19; 
20-24; 25-29; 30-34; 35-39; 40-45; 46-50; 51-55 years. 
5. Data analyses: Description of the data was made using simple 
frequencies of categorical variables (most probable area of infection; 
circumstances of exposure; results of MST, parasitological, serological 
and histopathological exams; co-morbidities; number of lesions; site of 
lesions; and age of lesions), and with average and minimum/maximum 
of continuous variables (number of lesions; MST in millimeters; duration 
of disease before treatment; and time until the occurrence of therapeutic 
failure).
The McNemar test was used for comparison of categorical variables 
between cases and controls, and the Wilcoxon test was used for 
continuous variables, when normality hypothesis was rejected by the 
Kolmogorov-Smirnov test. 
Simple models of binary conditional logistic regression were used 
to evaluate the effect of each variable in the occurrence of therapeutic 
failure (age of cutaneous lesion, number of lesions, site of lesions, 
co-morbidities, MST in millimeters, and positivity of serology, 
histopathology and culture). After that, a multiple model was performed 
to therapeutic failure, adjusted by the same characteristics. The likelihood 
ratio test was used to indicate the best adjusted model. Odds ratio (OR) 
and its respective confidence interval (CI) was used as a measure of the 
association among the variables in the regression models. 
MST in millimeters was used and, due to the lack of normal 
distribution, it was performed using its logarithm. Consequently, the 
application of anti-logarithm was used to the analysis of the results. 
p-values < 0.05 indicated significant association in the performed 
tests.
Data were analyzed with the Statistical Package for the Social 
Sciences (SPSS-WIN) version 16.0 and STATA 10.0 softwares. 
RESULTS
From 800 ATL patients followed-up in the studied period, 634 
(79.25%) presented CL. Four hundred and seven individuals were 
excluded from the study (Fig. 1). 
From 227 eligible patients, 32 (14.1%) evidenced therapeutic failure, 
and 64 matched controls were selected, with 96 patients being included 
in the study. Studied population included 59.4% men, with age varying 
between five and 55 years. For 89.6%, the probable place of infection was 
Rio de Janeiro State and 64.6% were from rural areas. Ninety seven per 
cent of the studied patients lived and/or had previously been in endemic 
areas for the disease. All patients with negative MST resided in endemic 
areas. Three of the subjects had no data concerning the place of residence 
or travels to endemic areas, and all of them showed strong MST reaction.
Main exposure motive in 93.8% of the patients was domicile. Co-
morbidities were observed in 34.4% of the patients, the most frequent 
being anemia, arterial hypertension, thyroid disease, atopic disease, 
smoking and tuberculosis. Data regarding HIV-serology, use of drugs 
or other diseases that could compromise immunity were not found in 
the studied records.
Culture, serology and histopathology for leishmaniasis were positive 
in 78.1%, 62.5% and 63.5%, respectively. Among the case group, all 
patients had parasitological confirmed diagnosis. In the control group, 
60 patients had parasitological confirmation, two had epidemiological, 
clinical and serological diagnosis, and two had epidemiological and 
clinical diagnosis. As a prerequisite for inclusion in the control group, 
all patients had had a good response to antimonial treatment. All of the 
four control subjects who had no parasitological confirmed diagnosis 
underwent mycological examination with negative results; all of them 
had a positive MST; and two had chronic granulomatous infiltrate in 
histopathology of the cutaneous lesion, suggestive of leishmaniasis. 
No significant difference among these variables and the occurrence of 
therapeutic failure was found. 
Average time to detection of therapeutic failure after the end of 
the treatment was 93 days, varying from 18 to 316 days. In the control 
group, the average in days until definitive scar formation was 194 days 
and varied from 51 to 418 days. 
There was a significant difference in cases regarding the age of the 
skin lesion prior to the diagnosis. Cases with lesions that were less than 
two months old at the first appointment were 71.9%, compared to 35.9% 
for controls (p < 0.001). 
MST reactivity in millimeters also exhibited significant difference 
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between cases and controls (p = 0.027). In cases, MST varied from 0 to 
60 mm, with median of 13.5 mm; and in controls, it varied from 0 to 50 
mm, with median of 17.5 mm. However, significant difference between 
groups was not observed when comparing MST using 5 mm as a cut-off 
(positive or negative) (p = 0.289). 
Age of skin lesion and the LogMST were significant regarding the 
occurrence of therapeutic failure in the simple model of conditional 
logistic regression, p < 0.001 and p = 0.026, respectively. Other 
variables (number of lesions, site of the lesion, co-morbidities, serology, 
histopathology and culture) were not statistically significant in the simple 
regression model (Table 1). 
The likelihood ratio test indicated a final multiple logistic model 
constituted by the LogMST in millimeters (adjusted OR: 0.26 / CI: 
[0.09 - 0.77] / p = 0.015) and by the age of the skin lesion (adjusted 
OR: 6.33 / CI: [2.52 - 15.90] / p < 0.001), and there was no significant 
interaction between these two variables. Patients with skin lesions 
less than two months old had 5.33 more chances of therapeutic failure 
than those with skin lesions more than two months old. For each 10 
millimeters of increase in MST, there was a decrease of 26% in the 
chances of occurrence of failure. 
Fig. 1 - Selection of cases and controls after analysis of the Data Bank of Lab Vigileish, INI/FIOCRUZ, 1989 to 2009, Rio de Janeiro, Brazil. 
Table 1
Odds ratio (non-adjusted) of the conditional simple logistic regression model
Variables ORa 95% CI p-value
Evolution time before treatment 5.64 [2.35 - 13.53] < 0.001
LogMSTb 0.32 [0.12 - 0.87] 0.026
Number of lesions 1.19 [0.53 - 2.68] 0.679
Site of the lesion 1.15 [0.56 - 2.37] 0.712
Co-morbidities 0.60 [0.25 - 1.47] 0.268
Serology positivity 1.76 [0.55 - 5.64] 0.345
Histopathology positivity 1.75 [0.70 - 4.34] 0.229
Culture positivity 1.23 [0.26 - 5.69] 0.793
aodds ratio; bLog skin test Montenegro results in millimiters.
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DISCUSSION
This study evaluated the association between therapeutic response 
and clinical and laboratory parameters, defined as age of skin lesion 
and MST. 
An inverse association between the intensity of MST reaction and 
the occurrence of therapeutic failure was observed, with strong reactors 
to MST being less susceptible to the occurrence of treatment failure. 
There was a significantly higher chance of development of therapeutic 
failure in patients with lesions less than two months old at the first 
appointment. 
The percentage of therapeutic failure (14%) was lower than 
reported in previous studies with meglumine antimoniate treatment 
(46% to 75%)12,27,29,33. Low failure rates found in this study support 
the effectiveness of low-dose treatment (5 mg Sb5+/kg/day) previously 
reported in studies at INI/FIOCRUZ19,29.
The fact that the majority of the studied population acquired 
the infection at their domicile is consistent with the peri-urban 
epidemiological profile of the disease in Rio de Janeiro6. Most of the 
subjects were from the state of Rio de Janeiro, where Leishmania 
(Viannia) braziliensis is responsible for almost all cases11. 
MST has been used since the 1920s, when it was developed by 
MONTENEGRO17. The importance of the standardization of the 
technique (application and reading) of MST and of the used antigen for 
its performance has been highlighted by several authors. The test must 
be performed by a trained technician, in order to assure comparable 
results and to avoid common causes of variation in the execution and 
interpretation of cutaneous tests, as follows: the amount of injected 
antigen; the site and deepness of the injection; the physiological 
status of the patient; the used vehicle; and the observer performing the 
measure3,16,35. Patients seen at Lab Vigileish, who performed MST in the 
institution, are always submitted to a standard protocol, ensuring the 
quality of the assistance in the test.
The safety and quality of the used antigen was ensured with the use 
of the antigen delivered by the Brazilian Ministry of Health, produced 
on a large scale within the standards of good practices1. Although the 
used strain is Leishmania (Leishmania) amazonensis, it is produced to 
be used throughout the country, regardless of the species of Leishmania 
causing disease.
The main difficulty found in the study was the incomplete patients’ 
records. The use of electronic records, however, turned easier the process 
of data collection. 
Study population of referral centers have characteristics which 
may differ from the general population, and this is a possible selection 
bias in this study. An assessment of all patients with poor response to 
treatment followed-up during the study, in addition to the matching 
between groups, was the strategy chosen to decrease biases. However, 
internal validity of the study was guaranteed by homogeneity in the 
distribution of the groups. 
Previous studies demonstrated higher rates of therapeutic failure in 
patients treated before the development of the cutaneous lesion; in those 
ones, treatment did not prevent the occurrence of the lesion14,34.
Reactivity to MST reflects the development of specific Th1 cellular 
immune response to the Leishmania parasite28. The development of 
adaptive immune response against leishmaniasis is the basis for the 
resistance to infection4. Usually, MST is used as an indicator of protection 
in vaccine evaluation studies against Leishmania9,10.
MST indicates the establishment of a cellular immune response 
against Leishmania antigens2,4,23. Low percentage of negative response 
to MST in this study confirms the high sensitivity of the test7,17,25,30. The 
proportion of patients with negative MST in the case group was twice 
that of the control group. The lack of statistical significance in MST 
analysis when classified in positive or negative may be related to the low 
proportion of negative tests27. PASSOS et al. suggested that a negative 
response to MST may function as a predictor of post-treatment relapse22. 
A defect of the host cellular immune response associated with the 
persistence of the parasite is a hypothesis to the occurrence of therapeutic 
failure or relapse5,26,32. A negative response to MST after two months 
of disease evolution may be related to a defect of the host immune 
response. However, patients presenting definitive cure with negative 
MST indicate that other factors may also be related to the occurrence of 
cure or therapeutic failure. 
Additional studies with the standard dose of meglumine antimoniate for 
CL (10 - 20 mg Sb5+/kg/day during 20 continuous days) and with different 
populations in other locations should be performed to confirm these results. 
CONCLUSION
Early treatment, reflected by an evolution time of the lesion of less 
than two months at the first appointment, and a poor cellular immune 
response, reflected by a less intense MST, both demonstrated to contribute 
to the occurrence of treatment failure in cutaneous leishmaniasis in CL 
patients with intramuscular meglumine antimoniate in the dose of 5 mg 
Sb5+/kg/day for 30 consecutive days. Clinicians should be aware of the 
possibility of therapeutic failure in the follow-up of negative MST patients 
and those who undergo treatment before the skin lesion is two months old.
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RESUMO
Intensidade da intradermorreação de Montenegro e tempo de 
evolução da lesão como preditores de falha na resposta terapêutica 
da leishmaniose cutânea
Conduzimos estudo caso-controle que verificou a associação entre 
a intradermorreação de Montenegro (IDRM), o tempo de evolução da 
lesão e a resposta terapêutica em pacientes com leishmaniose cutânea 
(LC) atendidos no Instituto de Infectologia Evandro Chagas (INI), 
Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brasil. Para cada 
caso com má resposta à terapêutica foram selecionados aleatoriamente 
dois controles que evoluíram com cicatrização das lesões após o 
tratamento, pareados por sexo e idade. Todos os pacientes realizaram 
tratamento com antimoniato de meglumina (Sb5+) IM, na dose de 5 mg 
Sb5+/kg/dia, continuamente, por 30 dias. Pacientes com LC apresentaram 
aproximadamente cinco vezes mais chance de falhar quando as lesões 
apresentavam menos de dois meses de evolução no primeiro dia de 
atendimento. Pacientes com falha terapêutica apresentaram reações de 
IDRM menos intensas que pacientes que evoluíram para a cura clínica. A 
cada 10 milímetros de aumento na resposta à IDRM, houve uma redução 
de 26% na chance de ocorrência de falha. O tratamento precoce, traduzido 
pelo tempo de evolução da lesão menor que dois meses no primeiro dia 
de atendimento, e resposta de imunidade celular deficiente, traduzida 
por IDRM menos intensa, demonstraram contribuir para a ocorrência 
de falha terapêutica na leishmaniose cutânea. 
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